Sponsored by NASHNP, AAOMP American Academy of Oral & Maxillofacial Pathology, The British Society for Oral and Maxillofacial Pathology, International Association of Oral and Maxillofacial Pathologists

Nodal Excisions and Neck Dissection Specimens for Head and Neck Tumours Histopathology Reporting Guide

ICCR

Family/Last name

Given name(s)

Date of birth DD – MM – YYYY

Patient identifiers

Date of request DD – MM – YYYY

Accession/Laboratory number

Elements in **black text** are CORE. Elements in **grey text** are NON-CORE.

☐ indicates multi-select values ◯ indicates single select values

SCOPE OF THIS DATASET

CLINICAL INFORMATION

- ◯ Information not provided
- ◯ Information provided (select all that apply)
  - ☐ Previous therapy
    - ☐ Surgery
    - ☐ Chemotherapy
    - ☐ Radiotherapy
    - ☐ Targeted therapy, *specify if available*
    - ☐ Immunotherapy, *specify if available*
  - ☐ Clinical staging, *specify*
  - ☐ Other clinical information, *specify*

OPERATIVE PROCEDURE

- ◯ Not specified
- ◯ Lymph node biopsy, *specify site*
- ◯ Selective neck dissection
  - ◯ Supraomohyoid
  - ◯ Lateral
  - ◯ Posterolateral
  - ◯ Central (anterior) compartment
- ◯ Comprehensive neck dissection
  - ◯ Modified radical neck dissection
  - ◯ Radical neck dissection
  - ◯ Extended radical neck dissection
- ◯ Other, *specify*

SPECIMEN(S) SUBMITTED (select all that apply)

- ☐ Left
  - ☐ Lymph nodes
    - ◯ Not specified
    - ☐ Submental (IA)
    - ☐ Submandibular (IB)
    - ☐ Upper jugular (II)
    - ☐ Middle jugular (III)
    - ☐ Lower jugular (IV)
    - ☐ Posterior triangle (V)
    - ☐ Retropharyngeal
    - ☐ Parotid/periparotid
    - ☐ Perifacial
    - ☐ Other, *specify*
  - ☐ Non-lymphoid tissue
    - ☐ Nerve
    - ☐ Muscle
    - ☐ Vein
    - ☐ Salivary gland
    - ☐ Other, *specify*
- ☐ Right
  - ☐ Lymph nodes
    - ◯ Not specified
    - ☐ Submental (IA)
    - ☐ Submandibular (IB)
    - ☐ Upper jugular (II)
    - ☐ Middle jugular (III)
    - ☐ Lower jugular (IV)
    - ☐ Posterior triangle (V)
    - ☐ Retropharyngeal
    - ☐ Parotid/periparotid
    - ☐ Perifacial
    - ☐ Other, *specify*
  - ☐ Non-lymphoid tissue
    - ☐ Nerve
    - ☐ Muscle
    - ☐ Vein
    - ☐ Salivary gland
    - ☐ Other, *specify*
- ☐ Central compartment lymph nodes (VI +/- VII)
  - ◯ Non-lymphoid tissue
    - ☐ Thymus
    - ☐ Parathyroid
    - ☐ Other, *specify*

Version 2.1 Published July 2024 ISBN: 978-1-922324-49-8

BLOCK IDENTIFICATION KEY

(List overleaf or separately with an indication of the nature and origin of all tissue blocks)

HISTOLOGICAL TUMOUR TYPE (select all that apply)

(Value list based on the World Health Organization Classification of Head and Neck Tumours (2024))

Primary tumour site

- ◯ Not specified/Not known
- ◯ Known (e.g., oral cavity, larynx), *specify*

Squamous cell carcinoma

- ☐ Squamous cell carcinoma, conventional
- ☐ HPV-associated oropharyngeal carcinoma
- ☐ Basaloid squamous cell carcinoma
- ☐ Papillary squamous cell carcinoma
- ☐ Spindle cell squamous carcinoma (sarcomatoid carcinoma)
- ☐ Adenosquamous cell carcinoma
- ☐ Acantholytic squamous cell carcinoma
- ☐ Undifferentiated (lymphoepithelial) carcinoma

Nasopharyngeal carcinoma

- ◯ Squamous cell carcinoma, keratinising
- ◯ Squamous cell carcinoma, non-keratinising (undifferentiated)
- ◯ Squamous cell carcinoma, basaloid
- ◯ Nasopharyngeal papillary adenocarcinoma

Neuroendocrine neoplasm, *specify type*

Mucosal melanoma, *specify*

Salivary gland carcinoma

- ☐ Mucoepidermoid carcinoma
- ☐ Adenoid cystic carcinoma
- ☐ Acinic cell carcinoma
- ☐ Secretory carcinoma
- ☐ Microsecretory adenocarcinoma
- ☐ Polymorphous adenocarcinoma
  - ◯ Classic ◯ Cribriform
- ☐ Epithelial-myoepithelial carcinoma
- ☐ Hyalinising clear cell carcinoma
- ☐ Basal cell adenocarcinoma
- ☐ Sebaceous adenocarcinoma
- ☐ Intraductal carcinoma
- ☐ Salivary duct carcinoma
- ☐ Myoepithelial carcinoma
- ☐ Carcinoma ex pleomorphic adenoma, *specify type(s)*
- ☐ Lymphoepithelial carcinoma
- ☐ Squamous cell carcinoma
- ☐ Oncocytic carcinoma
- ☐ Carcinosarcoma
- ☐ Adenocarcinoma, NOS

Other (e.g., primary adnexal skin cancers), *specify*

Comments

HISTOLOGICAL TUMOUR GRADE[a]

(Not applicable to all tumours)

- ◯ Not applicable
- ◯ Grade 1, well differentiated, low grade
- ◯ Grade 2, moderately differentiated, intermediate grade
- ◯ Grade 3, poorly differentiated, high grade
- ◯ Undifferentiated
- ◯ High grade transformation

Grading system used, *specify*

- ◯ Cannot be assessed, *specify*

[a] *Grading of neuroendocrine tumours is non-core. Use only Grade 1, 2 and 3 for neuroendocrine tumours; neuroendocrine carcinomas are considered high grade by definition and are therefore not graded.*

MARGIN STATUS

Involvement of perinodal surgical margin

- ◯ Not involved by carcinoma

  Specify closest margin(s), if possible

- ◯ Involved by carcinoma (select all that apply)
  - ☐ Left ☐ Right
  - ☐ Central ◯ Laterality not specified

  Lymph node level/compartment, *specify*

- ◯ Cannot be assessed, *specify*

See page 3 for LYMPH NODE STATUS (Note 8) and page 4 for SENTINEL LYMPH NODE BIOPSY (Note 9)

OTHER PATHOLOGY

ANCILLARY STUDIES

- ◯ Not performed
- ◯ Performed (select all that apply)
  - ☐ HPV testing,[b] *specify method and results*
  - ☐ EBV testing,[c] *specify method and results*
  - ☐ Other, *record test(s), methodology and results*

Representative blocks for ancillary studies, *specify those blocks best representing tumour and/or normal tissue for further study*

[b] *Core for metastases of squamous cell carcinoma to level II or III lymph nodes, with an unknown primary.*

[c] *Core for carcinomas with a lymphoepithelial pattern.*

Version 2.1 Published July 2024 ISBN: 978-1-922324-49-8

LYMPH NODE STATUS (select all that apply)

☐ **Left sided lymph nodes**

Node level	Number of nodes examined[d]	Number of nodes positive[d]	Extranodal extension (ENE)[e] o Not identified o ENEmi (≤2 mm) o ENEma (>2 mm)
Submental IA			
Submandibular IB			
Upper jugular II			
Middle jugular III			
Lower jugular IV			
Posterior triangle V			

[d] *Insert 'cannot be determined' when applicable.* [e] *Non-core element for HPV-associated oropharyngeal cancer and nasopharyngeal cancer.*

Maximum dimension of largest lymph node metastasis ____ mm

Maximum dimension of largest involved lymph node ____ mm

Specify site (level)

Greatest extent of extranodal extension (ENE) ____ mm

Specify site (level)

Soft tissue metastasis

◯ Not identified

◯ Present, *specify site (level)*

Non-lymphatic structures involved (select all that apply)

◯ Not identified

☐ Vessel

☐ Named vessel, *specify*

☐ Nerve

☐ Named nerve, *specify*

☐ Skeletal muscle

☐ Named skeletal muscle, *specify*

☐ Other, *specify*

☐ **Right sided lymph nodes**

Node level	Number of nodes examined[d]	Number of nodes positive[d]	Extranodal extension (ENE)[e] o Not identified o ENEmi (≤2 mm) o ENEma (>2 mm)
Submental IA			
Submandibular IB			
Upper jugular II			
Middle jugular III			
Lower jugular IV			
Posterior triangle V			

[d] *Insert 'cannot be determined' when applicable.* [e] *Non-core element for HPV-associated oropharyngeal cancer and nasopharyngeal cancer.*

Maximum dimension of largest lymph node metastasis ____ mm

Maximum dimension of largest involved lymph node ____ mm

Specify site (level)

Greatest extent of ENE ____ mm

Specify site (level)

Soft tissue metastasis

◯ Not identified

◯ Present, *specify site (level)*

Non-lymphatic structures involved (select all that apply)

◯ Not identified

☐ Vessel

☐ Named vessel, *specify*

☐ Nerve

☐ Named nerve, *specify*

☐ Skeletal muscle

☐ Named skeletal muscle, *specify*

☐ Other, *specify*

Version 2.1 Published July 2024 ISBN: 978-1-922324-49-8

LYMPH NODE STATUS (select all that apply) **continued**

☐ **Central compartment lymph nodes**

Number of nodes examined[d]

Number of nodes positive[d]

ENE[e]

- ◯ Not identified
- ◯ ENEmi (≤2 mm)
- ◯ ENEma (>2 mm)

Maximum dimension of largest lymph node metastasis mm

Maximum dimension of largest involved lymph node mm

Specify site (level)

Greatest extent of ENE mm

Specify site (level)

Soft tissue metastasis

- ◯ Not identified
- ◯ Present, *specify site (level)*

Non-lymphatic structures involved (select all that apply)

- ◯ Not identified
- ☐ Vessel
- ☐ Named vessel, *specify*
- ☐ Nerve
- ☐ Named nerve, *specify*
- ☐ Skeletal muscle
- ☐ Named skeletal muscle, *specify*
- ☐ Other, *specify*

[d] *Insert 'cannot be determined' when applicable.*

[e] *Non-core element for HPV-associated oropharyngeal cancer and nasopharyngeal cancer.*

SENTINEL LYMPH NODE BIOPSY

Side

◯ Left ◯ Right

Specific site, if known

Number of nodes examined

Number of nodes positive

Status of positivity of largest metastatic deposit

- ◯ Metastasis (>2 mm)
- ◯ Micrometastasis (0.2-2 mm)
- ◯ Isolated tumour cells (<0.2 mm or isolated cell clusters)

ENE

◯ Not identified ◯ Present

Go back to page 2 for OTHER PATHOLOGY (Note 10) and ANCILLARY STUDIES (Note 11)

REGIONAL LYMPH NODE CATEGORISATION (UICC TNM 8th edition)[f]

TNM Descriptors (only if applicable) (select all that apply)

- ☐ r - recurrent
- ☐ y - during or following multimodality therapy

Regional lymph nodes (pN)

Primary carcinomas of the lip and oral cavity, major salivary glands, nasal cavity and paranasal sinuses, p16 negative oropharynx (HPV-independent), hypopharynx, larynx, cutaneous head and neck carcinomas (with the exception of Merkel cell carcinoma) and unknown primary squamous cell carcinomas that are p16 and EBV-negative

- ◯ NX[g] Regional lymph nodes cannot be assessed
- ◯ N0 No regional lymph node metastasis
- ◯ N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension without ENE
- ◯ N2 Metastasis described as:
  - ◯ N2a Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension with ENE or more than 3 cm but not more than 6 cm in greatest dimension without ENE
  - ◯ N2b Metastasis in multiple ipsilateral nodes, none more than 6 cm in greatest dimension, without ENE
  - ◯ N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension, without ENE
- ◯ N3a Metastasis in a lymph node more than 6 cm in greatest dimension without ENE
- ◯ N3b Metastasis in a lymph node more than 3 cm in greatest dimension with ENE, or multiple ipsilateral, or any contralateral or bilateral node(s) with ENE

HPV-MEDIATED (p16 POSITIVE) OROPHARYNGEAL (HPV-ASSOCIATED)

- ◯ NX[g] Regional lymph nodes cannot be assessed
- ◯ N0 No regional lymph node metastasis
- ◯ N1 Metastasis in 1 to 4 lymph node(s)
- ◯ N2 Metastasis in 5 or more lymph node(s)

NASOPHARYNGEAL CARCINOMA

- ◯ NX[g] Regional lymph nodes cannot be assessed
- ◯ N0 No regional lymph node metastasis
- ◯ N1 Unilateral metastasis in cervical lymph node(s), and/or unilateral or bilateral metastasis in retropharyngeal lymph nodes, 6 cm or less in greatest dimension, above the caudal border of cricoid cartilage
- ◯ N2 Bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the caudal border of cricoid cartilage
- ◯ N3 Metastasis in cervical lymph node(s) greater than 6 cm in dimension and/or extension below the caudal border of the cricoid cartilage

MUCOSAL MELANOMA

- ◯ NX[g] Regional lymph nodes cannot be assessed
- ◯ N0 No regional lymph node metastasis
- ◯ N1 Regional lymph node metastasis present

[f] *Reproduced with permission. Source: UICC TNM Classification of Malignant Tumours, 8th Edition, eds by James D. Brierley, Mary K. Gospodarowicz, Christian Wittekind. 2016, Publisher Wiley (incorporating any errata published up until 12th July 2024).*

[g] *NX should be used only if absolutely necessary.*

Version 2.1 Published July 2024 ISBN: 978-1-922324-49-8